NasdaqGS - Nasdaq Real Time Price USD

ImmunityBio, Inc. (IBRX)

3.4400
+0.2900
+(9.21%)
At close: June 9 at 4:00:00 PM EDT
3.4700
+0.03
+(0.87%)
After hours: June 9 at 7:53:43 PM EDT
Loading Chart for IBRX
  • Previous Close 3.1500
  • Open 3.2900
  • Bid 3.4000 x 8300
  • Ask 3.4900 x 8300
  • Day's Range 3.2300 - 3.5300
  • 52 Week Range 1.8300 - 7.6300
  • Volume 25,898,089
  • Avg. Volume 8,586,192
  • Market Cap (intraday) 3.036B
  • Beta (5Y Monthly) -0.06
  • PE Ratio (TTM) --
  • EPS (TTM) -0.5700
  • Earnings Date Aug 11, 2025 - Aug 15, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 11.40

ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California.

immunitybio.com

671

Full Time Employees

December 31

Fiscal Year Ends

Recent News: IBRX

View More

Performance Overview: IBRX

Trailing total returns as of 6/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

IBRX
34.38%
S&P 500 (^GSPC)
2.11%

1-Year Return

IBRX
43.61%
S&P 500 (^GSPC)
12.32%

3-Year Return

IBRX
11.11%
S&P 500 (^GSPC)
49.48%

5-Year Return

IBRX
39.12%
S&P 500 (^GSPC)
87.26%

Compare To: IBRX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: IBRX

View More

Valuation Measures

Annual
As of 6/9/2025
  • Market Cap

    3.04B

  • Enterprise Value

    3.50B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    82.14

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    112.13

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -55.62%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    31.22M

  • Net Income Avi to Common (ttm)

    -409.1M

  • Diluted EPS (ttm)

    -0.5700

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    61.59M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -251.77M

Research Analysis: IBRX

View More

Company Insights: IBRX

Research Reports: IBRX

View More

People Also Watch